Literature DB >> 21555347

FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma.

Hanna Bernstine1, Marius Braun, Nikolay Yefremov, Yechiel Lamash, Raz Carmi, Dorit Stern, Adam Steinmetz, Jacob Sosna, David Groshar.   

Abstract

PURPOSE: To prospectively determine whether fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) early dynamic blood flow estimates could be used to discriminate hepatocellular carcinoma (HCC) from background liver and to characterize HCC in patients with and those without angioinvasion; and to evaluate the association between blood flow measures at FDG PET/CT with metabolism in HCCs.
MATERIALS AND METHODS: Institutional review board approval and written informed consent were obtained for this prospective study. Twenty-one consecutive patients (mean age, 65 years) with 30 established HCCs (mean size, 5.5 cm; seven lesions in five patients with angioinvasion) underwent a blood flow study with an FDG dynamic scan divided into 18 sequences of 5 seconds each and a standard PET/CT scan. On the dynamic study, three independent operators obtained volumes of interest (VOIs) for which three blood flow estimates were calculated (hepatic perfusion index [HPI], time to peak [TTP], and peak intensity [PI]). On the late study, a VOI was placed on the fused scan for each HCC, and maximum standardized uptake value (SUV(max)) was obtained. By using a mixed-effects model analysis, comparison of blood flow estimates between HCC with and that without angioinvasion and background liver was performed. The association between blood flow estimates and SUV(max) was also assessed.
RESULTS: HPI and TTP showed better performance than did SUV(max) for discriminating HCC and background liver (areas under receiver operating characteristic curve: 0.96, 0.95, and 0.83, respectively; P < .05). HPI was higher in HCC in patients with angioinvasion (0.91 ± 0.15 [standard deviation]) than in those without angioinvasion (0.80 ± 0.18; P = .03). There was no difference in SUV(max) between HCC in patients with and those without angioinvasion (7.8 ± 2.9 vs 6.3 ± 3.4; P = .85). No clear association was found between HPI, PI, or TTP and SUV(max) (P = .49, .77, and .91, respectively).
CONCLUSION: Early dynamic blood flow FDG PET/CT may be used to help discriminate and characterize HCC tumors. © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21555347     DOI: 10.1148/radiol.11102350

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Modeling of Tracer Transport Delays for Improved Quantification of Regional Pulmonary ¹⁸F-FDG Kinetics, Vascular Transit Times, and Perfusion.

Authors:  Tyler J Wellman; Tilo Winkler; Marcos F Vidal Melo
Journal:  Ann Biomed Eng       Date:  2015-05-05       Impact factor: 3.934

2.  Multiparametric Cardiac 18F-FDG PET in Humans: Kinetic Model Selection and Identifiability Analysis.

Authors:  Yang Zuo; Ramsey D Badawi; Cameron C Foster; Thomas Smith; Javier E López; Guobao Wang
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2020-10-15

3.  Expert consensus on oncological [18F]FDG total-body PET/CT imaging (version 1).

Authors:  Haojun Yu; Yushen Gu; Wei Fan; Yongju Gao; Meiyun Wang; Xiaohua Zhu; Zhifang Wu; Jianjun Liu; Biao Li; Hubing Wu; Zhaoping Cheng; Shuxia Wang; Yiqiu Zhang; Baixuan Xu; Sijin Li; Hongcheng Shi
Journal:  Eur Radiol       Date:  2022-06-25       Impact factor: 5.315

4.  Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.

Authors:  Reiko Nakajima; Koichiro Abe; Tsunenori Kondo; Kazunari Tanabe; Shuji Sakai
Journal:  Eur Radiol       Date:  2015-09-24       Impact factor: 5.315

5.  Assessment of hemodynamics in a rat model of liver cirrhosis with precancerous lesions using multislice spiral CT perfusion imaging.

Authors:  Guolin Ma; Rongjie Bai; Huijie Jiang; Xuejia Hao; Zaisheng Ling; Kefeng Li
Journal:  Biomed Res Int       Date:  2013-06-20       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.